Cargando…

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

BACKGROUND: Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson’s disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, point...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majbour, Nour K., Vaikath, Nishant N., van Dijk, Karin D., Ardah, Mustafa T., Varghese, Shiji, Vesterager, Louise B., Montezinho, Liliana P., Poole, Stephen, Safieh-Garabedian, Bared, Tokuda, Takahiko, Teunissen, Charlotte E., Berendse, Henk W., van de Berg, Wilma D. J., El-Agnaf, Omar M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717559/ https://www.ncbi.nlm.nih.gov/pubmed/26782965 http://dx.doi.org/10.1186/s13024-016-0072-9

Ejemplares similares

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
por: Oosterveld, Linda P., et al.
Publicado: (2019)

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
por: Karampetsou, Mantia, et al.
Publicado: (2017)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy
por: Wu, Jia-Zhen, et al.
Publicado: (2019)

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts
por: Ardah, Mustafa T., et al.
Publicado: (2020)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity
por: Hmila, Issam, et al.
Publicado: (2022)

CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson′s Disease
por: Oosterveld, Linda P., et al.
Publicado: (2020)

Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
por: Ghanem, Simona S., et al.
Publicado: (2021)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies
por: Gupta, Vijay, et al.
Publicado: (2020)

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
por: Anagnostou, Dimitrios, et al.
Publicado: (2023)

Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism
por: van Rooijen, Bart D., et al.
Publicado: (2010)

Decrease in Plasma Levels of α-Synuclein Is Evident in Patients with Parkinson’s Disease after Elimination of Heterophilic Antibody Interference
por: Ishii, Ryotaro, et al.
Publicado: (2015)

Essential Role of Sperm-Specific PLC-Zeta in Egg Activation and Male Factor Infertility: An Update
por: Saleh, Alaaeldin, et al.
Publicado: (2020)

Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study
por: Donadio, V., et al.
Publicado: (2018)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

Microtubule Depolymerization Potentiates Alpha-Synuclein Oligomerization
por: Esteves, A. Raquel, et al.
Publicado: (2010)

α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers
por: Gorostidi, Ana, et al.
Publicado: (2012)

Acetylated α-Tubulin and α-Synuclein: Physiological Interplay and Contribution to α-Synuclein Oligomerization
por: Calogero, Alessandra Maria, et al.
Publicado: (2023)

Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD
por: Esteves, A. R., et al.
Publicado: (2011)

Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein
por: Roberts, Hazel L., et al.
Publicado: (2015)

Oligomerization by co-assembly of β-amyloid and α-synuclein
por: Kim, Jin Ryoun
Publicado: (2023)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Dopamine-Mediated Oxidation of Methionine 127 in α-Synuclein Causes Cytotoxicity and Oligomerization of α-Synuclein
por: Nakaso, Kazuhiro, et al.
Publicado: (2013)

Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients
por: Kang, Wenyan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_enva1617a4iv23n4r5goqh96b5